Street View: Thermo Fisher's recovery remains elusive

Thermo Fisher Scientific

24/04/2026 14:17

** Thermo Fisher Scientific TMO.N said on Thursday it does not expect demand from U.S. and Chinese academic and government customers to rebound this year, while cautioning about inflationary risks arising from war on Iran

** Median PT of 30 brokerages covering stock is $625; average rating "buy" - LSEG-compiled data

NO TURN YET

** Jefferies ("buy," PT: $585) says issue for TMO is same for broader tools group right now - sluggish underlying demand growth and no clear signs yet of inflection in end-market conditions

** Leerink Partners("outperform," PT: $600) says tools market has been under pressure for last three years and setup was assumed to be at least de-risked at this point (especially for sector leader like TMO) with growth and recovery around the corner

** J.P.Morgan ("overweight," PT: $600) says end-market improvement seems more gradual than initially hoped
** "But TMO well-positioned to gain share during recovery," JPM adds

** Morgan Stanley ("overweight," PT: $670) says TMO's results offered little reassurance that company can meet, let alone exceed, its 2026 guidance, with increasing dependence on stronger second-half performance

 (Reporting by Joel Jose in Bengaluru)

 ((joeljose@thomsonreuters.com))